lymphoma

(redirected from Anaplastic large cell lymphoma)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to lymphoma

a neoplasm of lymph tissue that is usually malignant

References in periodicals archive ?
A review of the Anaplastic Large Cell Lymphoma (ALCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Anaplastic large cell lymphoma of T-cell phenotype in acquired immunodeficiency syndrome.
Twenty-one cases consisted of non-mantle-cell lymphomas or leukemias (4 follicular lymphomas, 5 B-cell lymphomas, 5 anaplastic large cell lymphomas, 5 T-cell lymphomas, 1 acute promyelocytic leukemia, and 1 acute lymphocytic leukemia).
Takeda Pharmaceutical Company Limited ( Takeda ) announced today that "ADCETRIS 50mg for intravenous drip infusion" (brentuximab vedotin) ( ADCETRIS ) is now available for the treatment for patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma (HL) or Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL) in Japan.
Anaplastic large cell lymphoma is a rare form of non-Hodgkin lymphoma presenting commonly in young patients (median, 33 years), albeit carrying the best overall 5year survival rate (77%) among all high-grade lymphomas.
The same gene is disrupted in some cases of anaplastic large cell lymphoma (ALCL), a cancer of the lymph cells, and in patients with non-small cell lung cancer.
The implants were linked to the death of the French woman from a rare form of cancer, called anaplastic large cell lymphoma (ALCL), and are implicated in another seven or eight cancer cases.
A woman who died from anaplastic large cell lymphoma in France had implants from Poly Implant Prosthesis and more than 2,000 women have filed complaints against the firm.
Takeda Pharmaceutical Company Limited (TSE:4502) together with its wholly-owned subsidiary Millennium: The Takeda Oncology Company, today announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for ADCETRIS™ (brentuximab vedotin) for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
The FDA is asking health care professionals to report any confirmed cases of anaplastic large cell lymphoma (ALCL) in women with silicone gel- or saline-filled breast implants, citing concerns about a possible association.
Nasdaq:SGEN) today announced that Health Canada has issued a Notice of Compliance with conditions (NOC/c), authorizing marketing of ADCETRIS for two lymphoma indications: (1) the treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one multi-agent chemotherapy regimen.
Anaplastic large cell lymphoma (ALCL) has a propensity to involve extranodal sites, particularly skin and rarely other extranodal sites such as lung.
An announcement is made by Takeda Oncology Company and Takeda Pharmaceutical Company Limited conditional marketing authorization for ADCETRIS for two indications: (1) the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option, and (2) for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).